Last Updated : October 18, 2016
Details
FilesGeneric Name:
Daclizumab beta
Project Status:
Complete
Therapeutic Area:
Multiple Sclerosis, relapsing-remitting
Manufacturer:
Biogen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Zinbryta
Project Line:
Reimbursement Review
Project Number:
SR0508-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Multiple Sclerosis, relapsing
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : October 18, 2016